CIBC Asset Management Inc Buys 789 Shares of Humana Inc. (NYSE:HUM)

CIBC Asset Management Inc lifted its stake in shares of Humana Inc. (NYSE:HUM) by 4.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,544 shares of the insurance provider’s stock after acquiring an additional 789 shares during the period. CIBC Asset Management Inc’s holdings in Humana were worth $4,705,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV lifted its holdings in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Humana in the third quarter worth $31,000. Your Advocates Ltd. LLP lifted its stake in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the last quarter. Atwood & Palmer Inc. lifted its stake in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares during the last quarter. Finally, LRI Investments LLC lifted its stake in Humana by 1,021.4% in the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after purchasing an additional 143 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.29% of the company’s stock.

Humana Price Performance

Shares of HUM opened at $265.54 on Thursday. The firm’s 50-day simple moving average is $269.80 and its two-hundred day simple moving average is $291.28. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market cap of $31.97 billion, a PE ratio of 26.69, a price-to-earnings-growth ratio of 1.91 and a beta of 0.56.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Analysts anticipate that Humana Inc. will post 16.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on HUM. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Barclays boosted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Truist Financial boosted their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. JPMorgan Chase & Co. lowered their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.